Interprofessional Collaboration to Develop Patient Educational Tools for Oral Oncolytics (2021 Update)

Kristine B. LeFebvre • David DeRemer • Joshua Nubla • Julianne O. Darling • Michael Reff • Britny Rogala • Eve Segal • Marie Sirek

Background
The process for treatment planning, ordering, and administration of oral oncolytics typically differs from other routes of drug administration in oncology. Although many centers have established processes for patient education and administration of parenteral drugs through the infusion suite, often patients receiving oral therapies obtain and take their drugs independent of these long-standing processes, requiring a system for oral oncolytic education and adherence monitoring. Advanced practice providers, nurses, and pharmacists are often providing patient education for oral oncolytic therapies. A need was identified for clear, concise and unbranded educational tools for those working with these patients.

Methods
Timeline

October 2015
- The National Community Oncology Dispensing Association, Inc. founded and led the formation of a core leadership team with executive directors from the Association of Community Cancer Centers, Hematology/Oncology Pharmacy Association, and Oncology Nursing Society.
- Early meetings were held to support the need for oral chemotherapy education and build the leadership, implementation, and maintenance teams.

November 2015
- The legal framework, financial support, and general infrastructure were established. A memorandum of understanding was developed, and the group began meeting by conference call every three weeks.
- A collaboration was formed between the Association of Community Cancer Centers, Hematology/Oncology Pharmacy Association, National Community Oncology Dispensing Association, Inc., and Oncology Nursing Society.

August 2017
- The development process was outlined, and a file-sharing platform was selected for use. Website development began.
- A design template was created.
- A template of evidence-based symptom management instructions was created. All symptoms were included that affected 30% or more of patients. Black box warnings and serious side effects were also included.
- Production of the Oral Chemotherapy Education sheets began. Each education sheet was designed to include drug-specific content on approved uses, dosing schedule, food and drug interactions, safe storage and handling, side effects, pregnancy and contraception information, and further resources.
- Monthly meetings were continued to address process, design, content, and challenges.

March 2018
- A website containing all of the oral chemotherapy education sheets launched at http://oralchemoedsheets.com/.

Process for Oral Chemotherapy Education Sheet Development

OCE Sheet Draft Workflow:

- A new drug is approved by the FDA.
- HOPA drafts the OCE sheet.
- HOPA performs an initial review of content.
- Content is reviewed by ONS.
- ONS completes copyedit and layout.
- OCE Committee Chairs perform final review of content and formatting.
- NCODA posts the OCE sheet online.

OCE Sheet Maintenance Workflow:

- Regular Quarterly Scheduled Maintenance of OCE Material
- OCE Sheets are assigned to NCODA OCE Committee Members for review
- NCODA reviews for updates and changes to be approved by NCODA OCE Committee Chairs
- If changes are necessary, NCODA edits and OCE Sheet is approved online

Results
Following the initial launch in March 2018, access to the OCE sheets has continued to increase. In 2018, there were about 167,000 page views, averaging 540-600 views and about 70 new visitors each day. At the end of September 2019, there were 92 sheets available, with an average of 21,800 page views per month and close to 200,000 page views for the year.

Implementation Team

Julianne O. Darling, PharmD, BCOP
Oncology Clinical Pharmacist
Simon Cancer Center
Indiana University Health
Indianapolis, IN

David DeRemer, PharmD, BCOP, FCCP, FHOPA
Assistant Director of Clinical Therapeutics
UF Health Cancer Center
Gainesville, FL

Kristine B. LeFebvre, MSN, RN, RN-BC, AOCN®
Oncology Clinical Specialist
Oncology Nursing Society

Josh Nubla, PharmD
Manager, Stakeholder Engagement and Operations
National Community Oncology Dispensing Association
Syraucus, NY

Michael J. Reff, RPh, MBA
Founder/Executive Director
NCODA
Cazenovia, NY

Britny Rogala, PharmD, BCOP
Clinical Assistant Professor
Department of Pharmacy Practice
College of Pharmacy
University of Rhode Island
Kingston, RI

Eve Segal, PharmD, BCOP
Clinical Oncology Pharmacist
Seattle Cancer Care Alliance
University of Washington Medical Center
Seattle, WA

Marie Sirek, PharmD, BCACP
Clinical Pharmacy Specialist / Oral Oncology Billings Clinic
Billings, MT

Conclusion
Through the process of interprofessional collaboration, unbranded patient education tools have been developed to support nurses, pharmacists, and advanced practice providers assisting patients receiving oral oncolytics.